Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
MicroRNAs in Cancer Therapy 2.0
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

MicroRNAs in Cancer Therapy 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 25 June 2024 | Viewed by 2962

Special Issue Editor

Prof. Dr. Bonglee Kim

E-Mail Website
Guest Editor
Department of Pathology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
Interests: oncology; epigenetics; miRNA; natural products; cancer; antioxidants; apoptosis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

MicroRNAs (miRNAs) are small noncoding RNAs about 18–24 nucleotides in length that have roles in cellular homeostasis functions in proliferation, cell cycle, development, differentiation, growth, and apoptosis. Various human diseases, including multiple sclerosis, diabetes, nonalcoholic fatty liver disease, and cancer, are associated with deregulated miRNA expression. The aberrant expression of miRNAs is shown in various cancers. Recently, miRNAs were identified as potential biomarkers for cancer diagnosis and response to therapy. However, the full mechanism of miRNA in cancer therapy is still unknown. It has been reported that several drugs, including natural products, have an miRNA regulatory effect on cancer pathology, including apoptosis, autophagy, drug resistance, invasion, metastasis, angiogenesis, etc.

In the Special Issue of “MicroRNAs in Cancer Therapy”, the main topic of interest is recent advances in miRNA studies in cancer therapy.

Prof. Dr. Bonglee Kim
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • miRNA
  • cancer
  • apoptosis
  • proliferation
  • metastasis
  • resistance
  • chemotherapy
  • natural product
  • herbal medicine
  • plant extract
  • side effects of chemotherapy

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

26 pages, 1699 KiB  
Article
Serum microRNA Profiles and Pathways in Hepatitis B-Associated Hepatocellular Carcinoma: A South African Study
by Kurt Sartorius, Benn Sartorius, Cheryl Winkler, Anil Chuturgoon, Tsai-Wei Shen, Yongmei Zhao and Ping An
Int. J. Mol. Sci. 2024, 25(2), 975; https://doi.org/10.3390/ijms25020975 - 12 Jan 2024
Viewed by 931
Abstract
The incidence and mortality of hepatocellular carcinoma (HCC) in Sub-Saharan Africa is projected to increase sharply by 2040 against a backdrop of limited diagnostic and therapeutic options. Two large South African-based case control studies have developed a serum-based miRNome for Hepatitis B-associated hepatocellular [...] Read more.
The incidence and mortality of hepatocellular carcinoma (HCC) in Sub-Saharan Africa is projected to increase sharply by 2040 against a backdrop of limited diagnostic and therapeutic options. Two large South African-based case control studies have developed a serum-based miRNome for Hepatitis B-associated hepatocellular carcinoma (HBV-HCC), as well as identifying their gene targets and pathways. Using a combination of RNA sequencing, differential analysis and filters including a unique molecular index count (UMI) ≥ 10 and log fold change (LFC) range > 2: <−0.5 (p < 0.05), 91 dysregulated miRNAs were characterized including 30 that were upregulated and 61 were downregulated. KEGG analysis, a literature review and other bioinformatic tools identified the targeted genes and HBV-HCC pathways of the top 10 most dysregulated miRNAs. The results, which are based on differentiating miRNA expression of cases versus controls, also develop a serum-based miRNA diagnostic panel that indicates 95.9% sensitivity, 91.0% specificity and a Youden Index of 0.869. In conclusion, the results develop a comprehensive African HBV-HCC miRNome that potentially can contribute to RNA-based diagnostic and therapeutic options. Full article
(This article belongs to the Special Issue MicroRNAs in Cancer Therapy 2.0)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 889 KiB  
Review
Role of microRNAs in Chronic Lymphocytic Leukemia
by Francesco Autore, Alice Ramassone, Luca Stirparo, Sara Pagotto, Alberto Fresa, Idanna Innocenti, Rosa Visone and Luca Laurenti
Int. J. Mol. Sci. 2023, 24(15), 12471; https://doi.org/10.3390/ijms241512471 - 05 Aug 2023
Cited by 1 | Viewed by 1507
Abstract
Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults, with a highly variable clinical course. Improvement in the knowledge of the molecular pathways behind this disease has led to the development of increasingly specific therapies, such as BCR signaling [...] Read more.
Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults, with a highly variable clinical course. Improvement in the knowledge of the molecular pathways behind this disease has led to the development of increasingly specific therapies, such as BCR signaling inhibitors and BCL-2 inhibitors. In this context, the emerging role of microRNAs (miRNAs) in CLL pathophysiology and their possible application in therapy is worth noting. MiRNAs are one of the most important regulatory molecules of gene expression. In CLL, they can act both as oncogenes and tumor suppressor genes, and the deregulation of specific miRNAs has been associated with prognosis, progression, and drug resistance. In this review, we describe the role of the miRNAs that primarily impact the disease, and how these miRNAs could be used as therapeutic tools. Certainly, the use of miRNAs in clinical practice is still limited in CLL. Many issues still need to be solved, particularly regarding their biological and safety profile, even if several studies have suggested their efficacy on the disease, alone or in combination with other drugs. Full article
(This article belongs to the Special Issue MicroRNAs in Cancer Therapy 2.0)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop